3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Conditions
Neoplasms
3
Trigger Finger Disorder
1
Stomach Neoplasms
1
Pleural Effusion, Malignant
1
Pancreatic Neoplasms
1
Nose Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Ganglion Cysts
1
Esthesioneuroblastoma, Olfactory
1
Dupuytren Contracture
1
De Quervain Disease
1
Colorectal Neoplasms
1
Cognitive Dysfunction
1
Carpal Tunnel Syndrome
1
Cachexia
1
Biliary Tract Neoplasms
1
Interventions
Gemcitabine
45
Cisplatin
34
Oxaliplatin
23
Capecitabine
17
Fluorouracil
13
Leucovorin
12
pembrolizumab
11
lenvatinib
11
durvalumab
10
S 1 (combination)
10
Irinotecan
10
Bevacizumab
9
apatinib
7
Nivolumab
7
tremelimumab
6
Trastuzumab
5
envafolimab
4
atezolizumab
4
Injections
4
Docetaxel
4
trametinib
3
titanium silicide
3
tislelizumab
3
irinotecan sucrosofate
3
camrelizumab
3
Radiotherapy
3
Drug Therapy
3
zanidatamab
2
toripalimab
2
surufatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Biliary Tract Neoplasms
×
Ibuprofen
×
Clear all
NCT04907864
2021-06-01
MIRACLE
Kyunghee University Medical Center
Phase 2
Unknown
112 enrolled